Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
Intellia Therapeutics (NASDAQ:NTLA) shares rose 11% to $11.94 after its latest quarterly results. The company reported revenue of $7.7m, about 41% below analyst forecasts, while its statutory loss of $0.80 per share matched expectations. Analysts cut 2026 revenue to $52.3m (down 12%) and raised/kept losses at $3.18 per share, lowering the average price target 8.5% to $23.94.
How this was made
The 30-second read
Why it matters
Analysts downgraded 2026 revenue expectations and reduced the average price target, while keeping 2026 losses per share roughly unchanged, implying a more cautious revenue trajectory.
Market read
Traders may reassess NTLA’s forward revenue trajectory and valuation expectations based on the consensus haircut, but the piece is not a new primary disclosure beyond analyst estimate revisions.
What to watch
The article does not provide details on the drivers of the revenue miss or any upcoming catalysts; without that, the estimate cuts may overstate near-term risk.
Background
The article summarizes post-earnings analyst consensus for Intellia Therapeutics (NTLA) after a quarterly results release.
Ticker impact
Simply Wall St reports NTLA’s latest results missed revenue expectations and analysts cut 2026 revenue estimates while keeping losses per share steady.
Bias to downside or underperformance versus peers until new catalysts (next trial/data or guidance) offset the revenue haircut.
The only concrete, company-specific updates here are the post-results consensus changes: revenue estimate cut, price target reduction, and unchanged loss-per-share outlook.
Market effects
For gene-editing/biopharma sentiment, the piece reinforces that revenue misses can quickly lead to estimate compression even when losses per share are stable.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Limited, as it is a consensus-estimate recap rather than a global regulatory or clinical milestone.
Counterpoint
Stable loss-per-share expectations could indicate cost discipline, so the revenue miss may be timing-related rather than a fundamental deterioration.
Key entities
- companyIntellia Therapeutics, Inc.
Subject of the article; consensus estimates for 2026 revenue, losses per share, and price targets were updated after its latest quarterly results.
